Chemical subgroup
L01FX – Andere monoklonale Antikörper und Antikörper-Wirkstoff-Konjugate
56Decisions
88Patient groups
Added benefit by patient group
- Major2
- Considerable10
- Minor6
- Non-quantifiable20
- Not proven49
- Lesser benefit1
Decisions, newest first
- 2026-10-01BlenrepBelantamab-MafodotinNot proven: 2 of 2 patient groups
- 2026-10-01BlenrepBelantamab-MafodotinNon-quantifiable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2026-07-16ElahereMirvetuximab SoravtansinConsiderable
- 2026-07-02MinjuviTafasitamabNon-quantifiable: 2 of 2 patient groups
- 2026-03-19LynozyficLinvoseltamabNot proven: 2 of 2 patient groups
- 2026-02-19TivdakTisotumab VedotinNot proven: 3 of 3 patient groups
- 2026-01-22OrdsponoOdronextamabNot proven
- 2026-01-22OrdsponoOdronextamabNot proven: 2 of 2 patient groups
- 2025-11-20DatrowayDatopotamab deruxtecanNot proven: 3 of 3 patient groups
- 2025-11-06ColumviGlofitamabNot proven: 3 of 3 patient groups
- 2025-11-06ColumviGlofitamabNot proven: 2 of 2 patient groups
- 2025-08-21BlincytoBlinatumomabConsiderable
- 2025-08-21BlincytoBlinatumomabNon-quantifiable
- 2025-08-21BlincytoBlinatumomabNon-quantifiable
- 2025-07-17RybrevantAmivantamabNot proven
- 2025-07-17RybrevantAmivantamabNot proven: 2 of 2 patient groups
- 2025-07-17RybrevantAmivantamabMinor
- 2025-04-17TepkinlyEpcoritamabNot proven: 2 of 2 patient groups
- 2025-04-17VyloyZolbetuximabMinor
- 2025-04-03PadcevEnfortumab VedotinConsiderable: 1 of 2 patient groupsNon-quantifiable: 1 of 2 patient groups
- 2025-03-06TepkinlyEpcoritamabNot proven
- 2024-07-04ElrexfioElranatamabNot proven: 2 of 2 patient groups
- 2024-06-20PolivyPolatuzumab VedotinNot proven
- 2024-06-20PolivyPolatuzumab VedotinNot proven: 3 of 3 patient groups
- 2024-04-04TepkinlyEpcoritamabNon-quantifiable
- 2024-03-07TalveyTalquetamabNon-quantifiable
- 2024-02-15TecvayliTeclistamabNot proven
- 2024-02-15TrodelvySacituzumab govitecanConsiderable
- 2023-11-02Zynlonta Loncastuximab tesirinNot proven: 2 of 2 patient groups
- 2023-10-05Tremelimumab AstraZenecaTremelimumabNot proven: 2 of 2 patient groups
- 2023-10-05ImjudoTremelimumabNot proven: 2 of 2 patient groups
- 2022-12-15LunsumioMosunetuzumabNon-quantifiable
- 2022-12-01PadcevEnfortumab VedotinConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2022-07-07RybrevantAmivantamabNot proven: 2 of 2 patient groups
- 2022-05-19TrodelvySacituzumab govitecanMajor
- 2022-03-03MinjuviTafasitamabNon-quantifiable
- 2022-01-20BlincytoBlinatumomabMajor
- 2021-12-16AdcetrisBrentuximab VedotinMinor
- 2021-12-16EmplicitiElotuzumabConsiderable
- 2021-07-15BlincytoBlinatumomabNon-quantifiable
- 2021-06-03YervoyIpilimumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2020-12-03PoteligeoMogamulizumabNon-quantifiable
- 2019-09-05AdcetrisBrentuximab VedotinNon-quantifiable
- 2019-08-15YervoyIpilimumabConsiderable: 2 of 2 patient groups
- 2019-08-15BlincytoBlinatumomabNon-quantifiable
- 2019-08-15BlincytoBlinatumomabNon-quantifiable
- 2019-02-21MylotargGemtuzumab OzogamicinNon-quantifiable
- 2018-12-20YervoyIpilimumabNot proven: 2 of 3 patient groupsLesser benefit: 1 of 3 patient groups
- 2018-08-02YervoyIpilimumabNot proven
- 2018-07-05AdcetrisBrentuximab VedotinMinor
- 2017-12-07BlincytoBlinatumomabConsiderable
- 2017-01-19AdcetrisBrentuximab VedotinNon-quantifiable
- 2016-12-01EmplicitiElotuzumabMinor
- 2014-06-05YervoyIpilimumabNot proven: 2 of 2 patient groups
- 2013-05-16AdcetrisBrentuximab VedotinNon-quantifiable: 3 of 3 patient groups
- 2012-08-02YervoyIpilimumabConsiderable
Data status: 2026-10-29